South Delhi Pharma, New Delhi, India
TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral use.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
TRIUMEQ is a prescription medicine. TRIUMEQ is used for HIV infection Treatment.
INDICATIONS AND USAGE
TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) is indicated for the treatment of HIV-1 infection.
DOSAGE FORMS & STRENGTHS
Tablets: 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine.
Manufactured By: ViiV Healthcare
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Abacavir/dolutegravir/lamivudine (brand name Triumeq) is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: 600 mg abacavir (reverse transcriptase inhibitor), 50 mg dolutegravir (integrase inhibitor) and 300 mg lamivudine (nucleoside analog reverse transcriptase inhibitor).
The medication was developed by ViiV Healthcare and was approved for use in the United States and in the European Union in 2014.
Abacavir is a nucleotide reverse transcriptase inhibitor. Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain.
